ProShares Ultra NASDAQ Biotechnology
BIB
20 hedge funds and large institutions have $3.13M invested in ProShares Ultra NASDAQ Biotechnology in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 7 closing their positions.
0.64% less ownership
Funds ownership: 4.43% → 3.79% (-0.64%)
13% less funds holding
Funds holding: 23 → 20 (-3)
13% less capital invested
Capital invested by funds: $3.6M → $3.13M (-$477K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JF
Jump Financial
Chicago,
Illinois
|
+$215K |
| 2 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
+$202K |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$2.1K |
| 4 |
Rockefeller Capital Management
New York
|
+$168 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$84 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$641K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$455K |
| 3 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
-$233K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$80K |
| 5 |
DWP
Destiny Wealth Partners
Tavares,
Florida
|
-$22K |
BIB Hedge Fund Activity: Q2 2026 in Review
20 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2026, worth a combined $3.13M — down 13% from $3.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Jump Financial, opening a new position worth an estimated $215K. The largest seller was Citadel Advisors, exiting entirely with an estimated $641K sold.
- 20 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2026, down from 23 in Q1 2026.
- Funds reported $3.13M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2026, down 13% quarter-over-quarter.
- 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2026 and 7 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2026 was Jump Financial, an estimated $215K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2026 was Citadel Advisors, an estimated $641K sold.
Based on aggregated 13F filings for Q2 2026.